252 related articles for article (PubMed ID: 20951926)
1. New pharmacologic therapies in gastrointestinal disease.
Wallace JL; Ferraz JG
Gastroenterol Clin North Am; 2010 Sep; 39(3):709-20. PubMed ID: 20951926
[TBL] [Abstract][Full Text] [Related]
2. New pharmacologic approaches in gastroesophageal reflux disease.
Armstrong D; Sifrim D
Gastroenterol Clin North Am; 2010 Sep; 39(3):393-418. PubMed ID: 20951909
[TBL] [Abstract][Full Text] [Related]
3. Control of gastric acid secretion in health and disease.
Schubert ML; Peura DA
Gastroenterology; 2008 Jun; 134(7):1842-60. PubMed ID: 18474247
[TBL] [Abstract][Full Text] [Related]
4. Overview of 50 years' progress in upper gastrointestinal diseases.
Yeomans ND
J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S2-4. PubMed ID: 19799693
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological targets in gastro-oesophageal reflux disease.
Piche T; Galmiche JP
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):333-41. PubMed ID: 16364047
[TBL] [Abstract][Full Text] [Related]
6. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
Andersson K; Carlsson E
Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
Lazzaroni M; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
McCarthy DM
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039
[TBL] [Abstract][Full Text] [Related]
9. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
Robinson M
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
[TBL] [Abstract][Full Text] [Related]
10. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.
Shamburek RD; Schubert ML
Gastroenterol Clin North Am; 1992 Sep; 21(3):527-50. PubMed ID: 1355465
[TBL] [Abstract][Full Text] [Related]
11. [Medicamentous modification of gastrointestinal motility and secretion].
Allescher HD
Z Gastroenterol; 1991 Apr; 29 Suppl 3():27-30. PubMed ID: 1648290
[TBL] [Abstract][Full Text] [Related]
12. Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
Sanger GJ; Alpers DH
Neurogastroenterol Motil; 2008 Mar; 20(3):177-84. PubMed ID: 18257767
[TBL] [Abstract][Full Text] [Related]
13. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
Manabe N; Wong BS; Camilleri M
Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
[TBL] [Abstract][Full Text] [Related]
14. [Gastrointestinal motility disorders and drugs: cholinergic, anticholinergic, adrenergic, antiadrenergic and prokinetic drugs (part I)].
Jovanović-Mićić D; Janković S; Beleslin DB
Srp Arh Celok Lek; 1994; 122(1-2):50-4. PubMed ID: 17972806
[TBL] [Abstract][Full Text] [Related]
15. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005.
Hunt RH
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():10-9. PubMed ID: 16303032
[TBL] [Abstract][Full Text] [Related]
16. Tachykinin receptors as drug targets for motility disorders.
Hoogerwerf WA; Sarna SK
Dig Dis; 2006; 24(1-2):83-90. PubMed ID: 16699266
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for gastroesophageal reflux disease.
Boeckxstaens GE
Expert Opin Emerg Drugs; 2009 Sep; 14(3):481-91. PubMed ID: 19650746
[TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds.
Scarpignato C; Pelosini I
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472
[TBL] [Abstract][Full Text] [Related]
19. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
Jovanović-Mićić D; Samardzić R; Beleslin B
Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
Camilleri M
Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
[No Abstract] [Full Text] [Related]
[Next] [New Search]
